Zacks Research Has Bullish Estimate for PAHC FY2026 Earnings

Phibro Animal Health Corporation (NASDAQ:PAHC) – Investment analysts at Zacks Research upped their FY2026 earnings per share (EPS) estimates for shares of Phibro Animal Health in a report issued on Wednesday, April 8th. Zacks Research analyst Team now expects that the company will post earnings of $2.99 per share for the year, up from their prior estimate of $2.98. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Phibro Animal Health’s current full-year earnings is $1.95 per share. Zacks Research also issued estimates for Phibro Animal Health’s Q4 2026 earnings at $0.67 EPS, Q1 2027 earnings at $0.78 EPS, Q2 2027 earnings at $0.79 EPS, Q4 2027 earnings at $0.79 EPS, FY2027 earnings at $3.07 EPS and FY2028 earnings at $3.18 EPS.

Other equities research analysts also recently issued reports about the company. Morgan Stanley set a $49.00 price target on Phibro Animal Health in a report on Friday, February 6th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $37.50.

Phibro Animal Health Price Performance

Shares of NASDAQ PAHC opened at $58.66 on Thursday. Phibro Animal Health has a twelve month low of $16.16 and a twelve month high of $59.68. The company has a current ratio of 3.05, a quick ratio of 1.22 and a debt-to-equity ratio of 2.14. The company has a market capitalization of $2.38 billion, a price-to-earnings ratio of 26.07, a price-to-earnings-growth ratio of 0.85 and a beta of 0.69. The business has a 50 day simple moving average of $51.49 and a 200-day simple moving average of $44.21.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.18. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.The business had revenue of $373.91 million during the quarter, compared to the consensus estimate of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS.

Phibro Animal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, March 25th. Investors of record on Wednesday, March 4th were paid a dividend of $0.12 per share. This represents a $0.48 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date was Wednesday, March 4th. Phibro Animal Health’s dividend payout ratio is presently 21.33%.

Insider Buying and Selling

In related news, CEO Jack Bendheim sold 110,842 shares of the company’s stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $48.38, for a total transaction of $5,362,535.96. Following the completion of the transaction, the chief executive officer directly owned 122,958 shares in the company, valued at $5,948,708.04. This represents a 47.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last ninety days, insiders sold 316,472 shares of company stock worth $15,265,419. 50.13% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in PAHC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Phibro Animal Health by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock worth $260,000 after buying an additional 546 shares during the last quarter. Millennium Management LLC boosted its position in Phibro Animal Health by 74.3% during the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock worth $7,733,000 after acquiring an additional 154,281 shares during the period. Jane Street Group LLC boosted its position in Phibro Animal Health by 65.3% during the 1st quarter. Jane Street Group LLC now owns 33,917 shares of the company’s stock worth $724,000 after acquiring an additional 13,404 shares during the period. Cetera Investment Advisers boosted its position in Phibro Animal Health by 63.0% during the 2nd quarter. Cetera Investment Advisers now owns 18,830 shares of the company’s stock worth $481,000 after acquiring an additional 7,280 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in Phibro Animal Health by 2.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company’s stock worth $332,000 after acquiring an additional 363 shares during the period. 99.34% of the stock is currently owned by institutional investors.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.